Armata Pharmaceuticals (ARMP)
(Delayed Data from AMEX)
$2.56 USD
+0.02 (0.59%)
Updated Aug 8, 2024 10:00 AM ET
After-Market: $2.61 +0.05 (1.95%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Armata Pharmaceuticals, Inc. [ARMP]
Reports for Purchase
Showing records 1 - 20 ( 38 total )
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; AP-SA02 Phase 2a Study Continues to Advance
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Strategic Capital Management and Clinical Development Plans Position Phage for Success
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
AP-SA02 Continues Quest to diSArm S.aureus Infections; Phase 2a Trial Begins Dosing Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Busy Phage Time as Dr. Deborah Birx Takes Helm
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Phage Program Continues Making Strides Forward on the Clinical Front
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; Continued Expansion and Progress Across Phage Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Top-Line Data From Phase 1b/2a SWARMP. a Study; Important Next Step for Phage
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Hopefully Data Should Create a Big SWARMP. a of Interest; Phase 1b/2a Data Anticipated 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First Bacteriophage Conference Takeaways; Field Approaching Significant Inflection Point; Time to Pay Attention
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Moving Quickly Toward Potential to Kinetic Shift; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Portfolio Expands With Four Active Clinical Trials; Prepping for AP-SA02's Phase 1b/2a Trial in PJI
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Green Light From FDA to Initiate Phage Therapy For S. aureus associated PJI
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
disARm(ing) S.aureus Infections; Phase 1b/2a Trial of AP-SA02 Begins Dosing Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; With Big Boost to Balance Sheet, The Stage is Set to Continue Advancing Clinical Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Three Distinct Phage Formulations Set the Stage for Key Updates in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Bigger, Better, Stronger; Improved AP-PA02 Better Equipped to Tackle Bacterial Infection
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
S. aureus About to Get ''disARm''ed; Support Grows for AP-PA02
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results: Programs Marching as Planned Under a New Roof
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Funding Further Increases Visibility on AP-PA02; The Phage Thesis Continues to Build
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J